On April 11, 2023, ArteraAI, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, and the American Cancer Society, a leading cancer-fighting organization, announced a new relationship that will allow both parties to contribute to making progress against the more than 200 diseases we call cancer. This announcement comes on the heels of ArteraAI’s recent emergence from stealth mode, with $90M in funding to support thedistribution of its flagship test in prostate cancer, the ArteraAI Prostate Test. This is the first test to predict therapy benefit in localized prostate cancer. The funding will also foster the development of tests to support therapy personalization in other cancers.
Login Or Register To Read Full Story